For information about COVID-19, including symptoms, prevention and travel advice, please read our COVID-19 patient guide, visit the NYC Department of Health or call our hotline: (646) 697-4000. If you have developed a fever, cough, shortness of breath or other respiratory symptoms, please call your provider before visiting one of our practice locations.

Susan C. Pannullo, M.D.

You are here

Susan Pannullo, MD

Dr. Pannullo is the Director of Neuro-oncology and the Director of Neurosurgical Radiosurgery at the Weill Cornell Brain and Spine Center. Both a neurosurgeon and a neuro-oncologist, Dr.  Pannullo is board-certified in both neurology and neurological surgery, is fellowship trained in neuro-oncology, and has completed specialty training in stereotactic radiosurgery. She is one of the few neurosurgeons in the world with a neurosurgical practice focused only on stereotactic radiosurgery, and one of the few neurosurgeons in the country with access to a CyberKnife, Gamma Knife, and Linear Accelerator (LINAC) to conduct stereotactic radiosurgery procedures.

Read a story about one of Dr. Pannullo's patients: Saving Face

Dr. Pannullo received her undergraduate degree with honors in Anthropology from Cornell University in 1983 and her medical degree from Cornell University Medical College in 1987. Following a medicine internship at Harvard-Beth Israel Medical Center, she completed a neurology residency at New York Hospital-Cornell Medical Center in 1991. From 1991 to 1992, she was an American Cancer Society Fellow in Neuro-oncology at Memorial Sloan-Kettering Cancer Center. She then completed a second residency in neurological surgery at New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in 1997, becoming the program’s first female graduate.

Dr. Pannullo’s research background includes clinical studies at Memorial Sloan-Kettering Cancer Center as well as laboratory research at the National Institutes of Health in Bethesda, Maryland. She currently oversees and directs the department’s numerous single-center and multi-center brain tumor clinical trials.